Core Insights - Vitarylon, a clinical-stage biotechnology company, is focused on developing transformative therapies for age-related diseases and will present three posters at the 2025 Society for Neuroscience Annual Meeting in San Diego from November 15-19, 2025 [1]. Group 1: Poster Presentations - Poster 1: Development of a highly potent, brain-penetrant allosteric RIPK1 inhibitor for the treatment of neurodegenerative diseases, scheduled for November 17, 2025, from 8 AM to 12 PM (Pacific Time) [2]. - Poster 2: Dose-dependent and robust target engagement of a novel brain-penetrant SARM1 inhibitor (SIR2501) in healthy adult participants, scheduled for November 18, 2025, from 8 AM to 12 PM (Pacific Time) [2]. - Poster 3: Discovery of a non-covalent, allosteric SARM1 inhibitor that prevents axonal degeneration in vitro and in vivo, also scheduled for November 18, 2025, from 8 AM to 12 PM (Pacific Time) [2]. Group 2: Company Overview - Vitarylon has been operational since 2017 and is dedicated to discovering and developing breakthrough therapies for age-related degenerative diseases, focusing on key pathogenic mechanisms such as dysregulated cell death, uncontrolled inflammatory responses, and imbalanced energy homeostasis [3]. - The company is currently conducting clinical studies on molecules such as SIR2501, SIR4156, and SIR9900, while also advancing preclinical research efforts [3].

Core Insights - Vitarylon, a clinical-stage biotechnology company, focuses on developing transformative therapies for age-related diseases, has appointed two senior executives to enhance its research and development pipeline [2][6] Group 1: Executive Appointments - Nasir Khan, DVM, PhD, has been appointed as Senior Vice President of Preclinical Development effective October 20, 2025, bringing over 30 years of experience in drug safety evaluation and regulatory submissions [2][3] - Gary Ingenito, MD, PhD, will serve as Senior Vice President of Clinical Development starting November 1, 2025, with extensive experience in drug development across various therapeutic areas [2][4] Group 2: Company Strategy and Pipeline - The company aims to advance its R&D pipeline, which includes three clinical-stage projects and four promising molecules that could be first-in-class or best-in-class [2][6] - Vitarylon has a diverse project pipeline targeting key pathogenic mechanisms of age-related diseases, including dysregulated cell death and uncontrolled inflammation [6] Group 3: Leadership Experience - Nasir Khan has led the non-clinical safety evaluation of over 400 preclinical candidates and has been involved in the approval of 63 new drug applications, including notable drugs like Celebrex and Ibrance [3][4] - Gary Ingenito has over 30 years of experience in clinical research and regulatory affairs, having worked on drugs for various diseases, including neurodegenerative conditions [4][5]